HomeTrialNCT06585449
🔬NCT06585449Phase 1RECRUITING

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment66 participants
Primary Completion
Lead SponsorAlnylam Pharmaceuticals
Data Retrieved2026-04-11 02:53:26.219191+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.